SAM
SYRE icon

Sectoral Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Sectoral Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-518
Closed -$89K – 81
2019
Q2 		$89K Hold
518
– – 0.01% 85
2019
Q1 		$104K Hold
518
– – 0.01% 98
2018
Q4 		$97K Hold
518
– – 0.01% 94
2018
Q3 		$124K Buy
+518
New +$121K 0.01% 152

Other funds holding SYRE

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sectoral Asset Management's SYRE Position: Q3 2019 in Review

Sectoral Asset Management sold out of Spyre Therapeutics (SYRE) in Q3 2019, closing a stake of 518 shares — an estimated $89K sold.

Sectoral Asset Management first reported a position in SYRE in Q3 2018 and held it in 4 quarters. The position peaked at $124K in Q3 2018. 71 funds tracked by Wall St. Rank hold SYRE as of Q3 2019.

  • Sectoral Asset Management reported no remaining Spyre Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Sectoral Asset Management sold 518 Spyre Therapeutics shares in Q3 2019, an estimated $89K.
  • Sectoral Asset Management first reported a position in Spyre Therapeutics in Q3 2018 and held it in 4 quarters.
  • Sectoral Asset Management's Spyre Therapeutics position peaked at $124K in Q3 2018.
  • 71 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2019.

Based on Sectoral Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.